Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(100%)

Phase Distribution

Ph phase_2
1
33%
Ph early_phase_1
1
33%
Ph phase_4
1
33%

Phase Distribution

1

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Terminated3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 41 (33.3%)

Trials by Status

terminated3100%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_4

Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00907218
terminatedphase_2

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

NCT01560507
terminatedearly_phase_1

Smoking Cessation Treatment for Head and Neck Cancer Patients

NCT00931021

Clinical Trials (3)

Showing 3 of 3 trials
NCT00907218Phase 4

Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)

Terminated
NCT01560507Phase 2

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

Terminated
NCT00931021Early Phase 1

Smoking Cessation Treatment for Head and Neck Cancer Patients

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3